Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 30, 2026
TickeronGET DAILY SIGNALS
Why Is Alphatec Holdings (ATEC) Stock Down -32.63% Today?

Why Is Alphatec Holdings (ATEC) Stock Down -32.63% Today?

Key Takeaways

  • ATEC shares plunged about 32.63% in Friday's session after third-quarter results and full-year guidance fell short of Wall Street expectations.
  • The primary catalyst was a revenue miss driven by weaker-than-expected biologics attachment, which also forced the company to cut its fiscal 2026 outlook.
  • A BMO Capital downgrade to Market Perform from Outperform, with a price-target cut to $8 from $12, compounded the selling pressure.
  • Despite the shortfall, surgical hardware revenue grew 17% and case volumes rose roughly 20%, signaling resilient underlying demand for the company's spine procedures.
  • Traders are now watching whether the company can stabilize biologics performance and whether further analyst estimate revisions follow.
  • For more detail on Price Targets, Earnings, and Forecast data, explore the additional pages available for this ticker.
  • You can also explore Trending AI Robots to see AI-driven trading strategies that may be positioned around this and other symbols.

Opening Summary

Alphatec Holdings, Inc. (ATEC), a medical device company focused on spine surgery through its Alphatec Spine, EOS imaging, and SafeOp Surgical businesses, saw its stock tumble sharply in Friday's trading. After closing the prior session at $11.37, the shares were trading around $7.66 intraday, a decline of roughly 32.63%. The selloff followed the company's third-quarter earnings release, which missed consensus estimates and included a reduction to full-year revenue guidance, prompting at least one analyst downgrade.

Third-Quarter Revenue Miss and Guidance Cut

The dominant driver of the decline was Alphatec's third-quarter report. The company posted revenue of approximately $221.2 million, up 13% year over year but below the consensus estimate of around $225 million. Management attributed the shortfall primarily to lower biologics attachment, which reduced revenue-per-case and offset otherwise healthy procedure growth. The company said its GAAP net loss narrowed to about $5.5 million from $28.6 million a year earlier, but the top-line miss overshadowed that improvement.

More concerning for investors was the guidance revision. Alphatec cut its full-year 2026 revenue outlook to approximately $862 million, a reduction of roughly $20 million, as the biologics softness persisted through the fourth quarter. The company reiterated that improving biologics performance is a clear priority, but the combination of a revenue miss and a lowered forecast triggered an aggressive repricing of the shares.

Analyst Downgrade Weighs on Sentiment

The earnings-driven selloff was amplified by a downgrade from BMO Capital, which lowered ATEC to Market Perform from Outperform and cut its price target to $8 from $12. The analyst cited the flat biologics attachment, the $20 million guidance reduction, and a 5% decline in revenue per case, noting that the firm now models the company's 2027 revenue, EBITDA, and free cash flow below its long-range plan. While the broader analyst consensus remains at Buy with a significantly higher average target, the prominent downgrade reinforced the bearish narrative in the immediate term.

Market Context and Trading Activity

The magnitude of the move was driven by heavy volume, as the earnings release and analyst action prompted a sharp repricing well above typical daily activity. The decline also coincided with broader pressure on growth-oriented and technology-adjacent names, where cautious corporate guidance weighed on sentiment. However, ATEC's drop was primarily company-specific, reflecting disappointment in the biologics segment rather than a broad healthcare-sector selloff. The shares broke decisively below prior support levels, with the stock trading near multi-year lows as momentum turned sharply negative.

What Comes Next for ATEC

Looking ahead, investors will focus on whether Alphatec can demonstrate a turnaround in biologics attachment and revenue-per-case trends in the coming quarters. The company continues to point to strong underlying fundamentals, including 17% hardware growth, approximately 20% case-volume growth, and a 25% increase in new surgeon adoption, suggesting demand for its procedural solutions remains robust. Key uncertainties include the pace of biologics recovery, potential further estimate revisions from analysts, and the company's progress toward its long-range financial targets. With the stock now trading well below recent levels, the near-term path will likely hinge on execution in the biologics business and management's commentary on subsequent earnings calls.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and traded symbols. Only the strongest performers in the present environment are featured in this section. Explore the page to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ATEC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ATEC in downward trend: 10-day moving average crossed below 50-day moving average on November 03, 2026

The 10-day moving average for ATEC crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATEC as a result. In 65 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for ATEC turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 31 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

ATEC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATEC's RSI Oscillator exited the oversold zone, 28 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATEC advanced for three days, in 268 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

ATEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 217 of 253 cases where ATEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. ATEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (-95.212) is very low in comparison to the industry average of (4.142). P/E Ratio (-10.479) is within average values for comparable stocks, (3.291). ATEC's Projected Growth (PEG Ratio) (91.200) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.980) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company with interests in medical equipment and supplies

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1950 Camino Vida Roble
Phone
+1 760 431-9286
Employees
913
Web
https://www.atecspine.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.